Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
California
94080
United States
Tel: 650.246.7000
Fax: 650.246.7376
Website: http://www.portola.com/
Email: contact@portola.com
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
269 articles about Portola Pharmaceuticals, Inc.
-
Portola Pharmaceuticals, Inc. Announces Upcoming Oral Presentation of Data on PRT4445, a First-in-Class Universal Factor Xa Inhibitor Antidote, at European Society of Cardiology 2012 Congress
8/24/2012
-
Portola Pharmaceuticals, Inc. Appoints Robert M. Califf, M.D., to Board of Directors
8/2/2012
-
Portola Pharmaceuticals, Inc. Advances PRT4445, a First-in-Class Universal Factor Xa Inhibitor Antidote, Into Clinical Development
6/15/2012
-
Portola Pharmaceuticals, Inc. Initiates Global Pivotal Phase 3 Study of Factor Xa Inhibitor Betrixaban
3/30/2012
-
Portola Pharmaceuticals, Inc.'s J.P. Morgan Healthcare Conference Presentation Focused on Three Transformational Programs for 2012
1/13/2012
-
Portola Pharmaceuticals, Inc. Announces Completion of $89 Million Financing
11/21/2011
-
Biogen Idec, Inc. (Massachusetts), Portola Pharmaceuticals, Inc. Strike $553 Million Deal for Oral Syk Inhibitor
10/28/2011
-
Portola Pharmaceuticals, Inc. Announces Upcoming Oral Presentation of Factor Xa Inhibitor Antidote Data at European Society of Cardiology 2011 Congress
8/11/2011
-
Portola Pharmaceuticals, Inc. Names Dr. Michael Kitt as Chief Medical Officer
7/18/2011
-
Portola Pharmaceuticals, Inc. Appoints Dr. James Topper to Board of Directors
4/12/2011
-
Portola Pharmaceuticals, Inc. Announces Initiation of Phase 1 Multiple Ascending Dose Trial of Oral Syk-Specific Inhibitor
3/31/2011
-
Portola Pharmaceuticals, Inc. to Regain Global Rights for Investigational Medicine Betrixaban from Merck & Co., Inc.; Breaks $470 Million Pact Made in 2009
3/24/2011
-
Accumetrics, Inc. Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
3/2/2011
-
Portola Pharmaceuticals, Inc. Appoints John T. Curnutte, M.D., Ph.D., to Head R&D
1/24/2011
-
Portola Pharmaceuticals, Inc. Announces Presentation at J.P. Morgan's 29th Annual Healthcare Conference
1/5/2011
-
Portola Pharmaceuticals, Inc. Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
12/6/2010
-
Portola Pharmaceuticals, Inc. Announces Investigational Universal Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity of Factor Xa Inhibitors
11/15/2010
-
Portola Pharmaceuticals, Inc. Appoints Jean-Jacques Bienaime to Board of Directors
9/23/2010
-
Portola Pharmaceuticals, Inc. Announces That Phase 2 INNOVATE-PCI Trial With Elinogrel Achieved Objectives; Novartis AG to Start Final-Stage Test of Blood Thinner
8/31/2010
-
Merck & Co., Inc., Portola Pharmaceuticals, Inc. Blood Thinner Appears Safe, Effective-Study
3/15/2010